Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426865 · ClinicalTrials.gov registry record
Role of Axumin PET Scan in Germ Cell Tumor
A clinical trial of Germ Cell Tumor and Testicular Cancer, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 10
- Enrollment target
- 1
- Study location
NCT03426865 is a study of Germ Cell Tumor and Testicular Cancer that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 10 participants, below the 347-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03426865, a study of Germ Cell Tumor and Testicular Cancer, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
Conditions Studied
Interventions
- DRUG Axumin PET scan
Study Locations (1)
Texas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2023-06-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426865
The ClinicalTrials.gov registry entry for NCT03426865 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (97% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 1 intervention - of which Axumin PET scan is the first listed.
NCT03426865 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03426865 about?
NCT03426865 is a clinical study titled "Role of Axumin PET Scan in Germ Cell Tumor". Investigators will use Axumin PET/CT to help with the imaging modalities to determine the presence of occult retroperitoneal disease.
What is the current status of trial NCT03426865?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2018-03-01. Estimated completion is 2023-06-01.
What conditions does trial NCT03426865 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Testicular Cancer, Testicular Germ Cell Tumor, Testis Cancer, Testicular Diseases.
What interventions are being tested in trial NCT03426865?
The interventions under investigation include: Axumin PET scan (DRUG).
Who is sponsoring clinical trial NCT03426865?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03426865 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
RECRUITING · Phase 3
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.